- Marker Therapeutics Inc to Participate in the Beyond CAR-T: What's Next for Cell Therapy Event TranscriptAug 09, 2023
- Marker Therapeutics Inc to Host Clinical Program Update Call TranscriptFeb 16, 2022
- Marker Therapeutics Inc at Raymond James Human Health Innovation Conference (Virtual) TranscriptJun 21, 2021
- Q1 2021 Marker Therapeutics Inc Earnings Call TranscriptMay 12, 2021€19.1 (-1.04%)Earnings
- Q3 2020 Marker Therapeutics Inc Earnings Call TranscriptNov 09, 2020€12.7 (+8.55%)Earnings
- Marker Therapeutics Inc MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting TranscriptJun 01, 2020
- Q1 2020 Marker Therapeutics Inc Earnings Call TranscriptMay 11, 2020€22.8 (+8.57%)Earnings
- Q3 2019 Marker Therapeutics Inc Earnings Call TranscriptNov 12, 2019€35.64 (-0.03%)Earnings
- Marker Therapeutics Inc Special Call TranscriptJul 22, 2019
- Marker Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference TranscriptMay 16, 2019
Marker Therapeutics Inc MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting Transcript
Good morning, ladies and gentlemen, and welcome to Marker Therapeutics Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.
I would now like to turn the call over to Mr. Tony Kim, Chief Financial Officer at Marker. Please go ahead.
Thanks, and welcome, everyone. The press release containing the interim study results with our MultiTAA-specific T cell therapy in pancreatic cancer, as reported during the ASCO annual meeting late last week, are available in the News section of the Marker Therapeutics website.
Joining me for the call today are Peter Hoang, our Chief Executive Officer; Dr. Mythili Koneru, our Chief Medical Officer; and Dr. Brandon Smaglo, Lead Investigator for the TACTOPS trial. Dr. Smaglo is currently Associate Professor in the Department of Gastrointestinal Medical Oncology in the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center in Houston, Texas, and was formerly at the Baylor College of Medicine where he led the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)